Oglemilast

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOglemilast
Drug Alias Name奥米司特oglemilastoglemilastum欧来米特GRC-3836 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma, Exercise-InducedAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesForest Laboratories IncGlenmark Pharmaceuticals Europe Ltd
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma, Exercise-InducedAsthma

Other Information

ATC CodeN/A
Related LinksN/A